The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...
We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...
Abstract: Adaptive filters, constrained by a linear filtering framework, often struggle with nonlinear modeling in complex processes. Kernel adaptive filters (KAFs) offer a promising solution by ...
Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...
Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...
If Google’s AI researchers had a sense of humor, they would have called TurboQuant, the new, ultra-efficient AI memory compression algorithm announced Tuesday, “Pied Piper” — or, at least that’s what ...
As Large Language Models (LLMs) expand their context windows to process massive documents and intricate conversations, they encounter a brutal hardware reality known as the "Key-Value (KV) cache ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Recursion (RXRX). The reason why I want to go over this biotech next is because the company ...
The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results